JP2021523096A - 未治療対象において癌を治療する際に使用するための標的ｔｇｆ−β阻害のための投与計画 - Google Patents

未治療対象において癌を治療する際に使用するための標的ｔｇｆ−β阻害のための投与計画 Download PDF

Info

Publication number
JP2021523096A
JP2021523096A JP2020556807A JP2020556807A JP2021523096A JP 2021523096 A JP2021523096 A JP 2021523096A JP 2020556807 A JP2020556807 A JP 2020556807A JP 2020556807 A JP2020556807 A JP 2020556807A JP 2021523096 A JP2021523096 A JP 2021523096A
Authority
JP
Japan
Prior art keywords
seq
protein
polypeptide
sequence
tgfβ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020556807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523096A5 (https=
JPWO2019222252A5 (https=
Inventor
オジャルボ，ローリーン
バワブ，サメール エル
バワブ，サメール エル
デュサール，イザベル
ヴァグマイスター，ユリア
カーンデルワル，アカシュ
クリステンセン，オラフ
Original Assignee
メルク パテント ゲーエムベーハー
メルク パテント ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク パテント ゲーエムベーハー, メルク パテント ゲーエムベーハー filed Critical メルク パテント ゲーエムベーハー
Publication of JP2021523096A publication Critical patent/JP2021523096A/ja
Publication of JP2021523096A5 publication Critical patent/JP2021523096A5/ja
Publication of JPWO2019222252A5 publication Critical patent/JPWO2019222252A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2020556807A 2018-05-15 2019-05-14 未治療対象において癌を治療する際に使用するための標的ｔｇｆ−β阻害のための投与計画 Pending JP2021523096A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862671963P 2018-05-15 2018-05-15
US62/671,963 2018-05-15
US201962804931P 2019-02-13 2019-02-13
US62/804,931 2019-02-13
PCT/US2019/032271 WO2019222252A1 (en) 2018-05-15 2019-05-14 Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects

Publications (3)

Publication Number Publication Date
JP2021523096A true JP2021523096A (ja) 2021-09-02
JP2021523096A5 JP2021523096A5 (https=) 2022-05-18
JPWO2019222252A5 JPWO2019222252A5 (https=) 2022-05-18

Family

ID=68540945

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020556807A Pending JP2021523096A (ja) 2018-05-15 2019-05-14 未治療対象において癌を治療する際に使用するための標的ｔｇｆ−β阻害のための投与計画

Country Status (12)

Country Link
US (1) US20210061899A1 (https=)
EP (1) EP3813868A4 (https=)
JP (1) JP2021523096A (https=)
KR (1) KR20210009339A (https=)
CN (1) CN112118858A (https=)
AU (1) AU2019271065A1 (https=)
BR (1) BR112020021082A2 (https=)
CA (1) CA3096844A1 (https=)
MX (1) MX2020011638A (https=)
SG (1) SG11202011148VA (https=)
TW (1) TW202003577A (https=)
WO (1) WO2019222252A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020402496A1 (en) * 2019-12-11 2022-06-16 WuXi Biologics Ireland Limited Bi-functional antibody against PD-L1 and TGFβ
PH12022552826A1 (en) * 2020-04-28 2024-03-11 Sinocelltech Ltd TgfãŸr2 extracellular domain truncated molecule, fusion protein of tgfãŸr2 extracellular domain truncated molecule and anti-egfr antibody, and anti-tumor use of fusion protein
US20230365653A1 (en) * 2020-07-24 2023-11-16 Mabwell (shanghai) Bioscience Co., Ltd. Tgf-beta rii mutant and fusion protein thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017506217A (ja) * 2014-02-10 2017-03-02 メルク パテント ゲーエムベーハー 標的ＴＧＦβ阻害
US20180118832A1 (en) * 2016-08-12 2018-05-03 Merck Patent Gmbh Combination therapy for cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201216649D0 (en) * 2012-09-18 2012-10-31 Univ Birmingham Agents and methods
CA3081073C (en) * 2013-03-12 2023-09-12 Biocon Ltd. Fusion immunomodulatory proteins and methods for making same
US20170145103A1 (en) * 2015-11-23 2017-05-25 Five Prime Therapeutics, Inc. Predicting response to cancer treatment with fgfr2 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017506217A (ja) * 2014-02-10 2017-03-02 メルク パテント ゲーエムベーハー 標的ＴＧＦβ阻害
US20180118832A1 (en) * 2016-08-12 2018-05-03 Merck Patent Gmbh Combination therapy for cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RES. (2017) VOL.77, ISSUE 13 SUPPL., ABSTRACT 611, <HTTPS://AACRJOURNALS.ORG/CANCERRES/ARTICL, JPN6023009221, ISSN: 0005165105 *
J. IMMUNOTHER. CANCER (2017) VOL.5, SUPPL.2, 86, P.7-8, JPN6023009219, ISSN: 0005165107 *
ONCOIMMUNOLOGY (2017) VOL.6, NO.10, E1349589, P.1-16, JPN6023009220, ISSN: 0005165106 *

Also Published As

Publication number Publication date
CA3096844A1 (en) 2019-11-21
TW202003577A (zh) 2020-01-16
MX2020011638A (es) 2022-02-10
EP3813868A4 (en) 2022-03-02
EP3813868A1 (en) 2021-05-05
WO2019222252A1 (en) 2019-11-21
US20210061899A1 (en) 2021-03-04
SG11202011148VA (en) 2020-12-30
AU2019271065A1 (en) 2020-11-05
KR20210009339A (ko) 2021-01-26
CN112118858A (zh) 2020-12-22
BR112020021082A2 (pt) 2021-02-17

Similar Documents

Publication Publication Date Title
JP2020514290A (ja) 標的ｔｇｆ−β阻害のための投薬計画及び投薬形態
JP7448552B2 (ja) がんの併用療法
JP2021527083A (ja) ステージｉｉｉ ｎｓｃｌｃの治療及びその治療に伴う病理学的状態の鎮静
US20230131598A1 (en) Combination treatment for cancer
JP2025519495A (ja) がんを治療するための抗ｐｄ－１活性薬剤、抗ｔｉｍ－３活性薬剤、および抗ｌａｇ－３活性薬剤の併用療法
JP2021523096A (ja) 未治療対象において癌を治療する際に使用するための標的ｔｇｆ−β阻害のための投与計画
US20230140694A1 (en) Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
JP2021529777A (ja) 進行非小細胞肺癌の治療のための標的ＴＧＦ−β阻害による組み合わせ療法
JP2024529451A (ja) がんを治療するための方法及び組成物
US20230149543A1 (en) Combination treatment for cancer based upon an icos antbody and a pd-l1 antibody tgf-bets-receptor fusion protein
JP2021528399A (ja) 胆道癌を治療する際に使用するための標的ＴＧＦ−β阻害のための投薬計画
KR20250148463A (ko) 담도암의 치료를 위한 항-her2/항-4-1bb 이중 특이 항체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220509

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230607

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231003